Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lucentis Faces Academic Challenge

This article was originally published in The Pink Sheet Daily

Executive Summary

Funding for a multi-center trial to compare Genentech’s approved macular degeneration therapy with oncologic Avastin, used off-label to treat the disease, depends on NIH’s pending FY 2007 budget.

You may also be interested in...



NIH Kicks Off Head-To-Head Avastin/Lucentis Study

Outcome could hinder Genentech's Lucentis sales, if results show Avastin is more cost-effective.

NIH Kicks Off Head-To-Head Avastin/Lucentis Study

Outcome could hinder Genentech's Lucentis sales, if results show Avastin is more cost-effective.

Lucentis’ First Patients Mostly Taken From Macugen, Visudyne & Avastin – Genentech

The company recorded $153 mil. in sales for the macular degeneration product in its first full quarter on the market.

Related Content

Topics

UsernamePublicRestriction

Register

MT101489

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel